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In the present study, we characterized and compared the
mineral phase deposited in the aortic wall of two different
frequently used chronic renal failure rat models of vascular
calcification. Vascular calcification was induced in rats by
either a 4-week adenine treatment followed by a 10-week
high-phosphate diet or 5/6 nephrectomy followed by
6 weeks of 0.25 lg/kg/day calcitriol treatment and a
high-phosphate diet. Multi-element mapping for calcium
and phosphate together with mineral identification was
performed on several regions of aortic sections by means of
synchrotron X-ray-l-fluorescence and diffraction. Bulk
calcium and magnesium content of the aorta was assessed
using flame atomic absorption spectrometry. Based on the
diffraction data the Von Kossa-positive precipitate in the
aortic regions (N¼ 38) could be classified into three groups:
(1) amorphous precipitate (absence of any diffraction peak
pattern, N¼ 12); (2) apatite (N¼ 16); (3) a combination of
apatite and magnesium-containing whitlockite (N¼ 10). The
occurrence of these precipitates differed significantly
between the two models. Furthermore, the combination
of apatite and whitlockite was exclusively found in the
calcitriol-treated animals.
These data indicate that in adenine/phosphate-induced
uremia-related vascular calcification, apatite is the main
component of the mineral phase. The presence of
magnesium-containing whitlockite found in addition to
apatite in the vitamin D-treated rats, has to be seen in view
of the well-known vitamin D-stimulated gastrointestinal
absorption of magnesium.
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Cardiovascular events are responsible for almost 50% of the
mortality in hemodialysis patients. In patients with chronic
kidney disease, vascular disease is often accompanied by
arterial calcifications.1 Several investigators have shown that
coronary artery calcifications are already present in young
dialysis patients2,3 tend to progress rapidly4 and are
associated with decreased survival related to the vascular site
containing calcifications.5,6
Elevated serum phosphate levels, hyperparathyroidism,
and an increased Ca P product are identified as indepen-
dent risk factors for coronary artery calcifications.2,4 Treat-
ment of secondary hyperparathyroidism with calcitriol is
currently recommended in adult and pediatric patients with
chronic kidney disease.7,8 However, the suppressive effect of
calcitriol on parathyroid hormone release goes along with an
increased calcium/phosphorus gastrointestinal absorption,
favoring ectopic calcification.
Vascular calcification is a tightly regulated process driven
by specific cellular events9,10 and particular components
present in the serum.11 Transdifferentiation of vascular
smooth muscle cells towards cells with an osteogenic
phenotype, expressing the major bone-specific proteins, is a
key event in the process of medial calcification.12 Based on
these observations it is generally assumed that the mineral
deposited in the vascular wall has the physicochemical
properties of hydroxyapatite, the mineral compound of
bone. However, owing to the limited availability of appro-
priate techniques data on the identity and ultrastructural
composition of the mineral phase deposited during vascular
calcification are scarce.13,14
By the application of synchrotron radiation based X-ray
m-fluorescence in combination with m-diffraction analysis,
we studied the ultrastructural spatial composition of
the mineral deposited in the vessel wall of calcitriol- and
non-calcitriol-treated models of uremia-induced vascular
calcification.
RESULTS
Both rat models, that is, the combination of (i) adenine
treatment with a high-phosphate diet and (ii) 5/6 nephre-
ctomy, a high-phosphate diet, and oral dosing of calcitriol
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resulted in mineral deposition in the vascular wall, as could
be visualized by Von Kossa staining (data not shown).15,16
X-ray-m-fluorescence analysis was performed on aorta
samples obtained from rats of both models with a positive
Von Kossa staining. In all investigated microscopic aortic
regions of interest (N¼ 38) a positive X-ray fluorescence
signal for phosphorus and calcium was observed (Figure 1b
and c). By recording the X-ray diffraction patterns of several
calcium- and phosphorus-positive spots in the investigated
aortic regions three different types of mineral were identified
(Table 1): (i) amorphous calcium phosphate precipitate
in the absence of any diffraction peak pattern (N¼ 12), or
(ii) poorly crystalline apatite (microcrystalline or non-stoe-
chiometric apatite) (N¼ 16), or (iii) a combination of apatite
and whitlockite (N¼ 10) (Figure 1d). The occurrence of the
various types significantly (Po0.05) differed between the two
models and the combination of apatite and whitlockite
mineral was exclusively found in vitamin D-treated animals
(Table 1).
The spatial heterogeneity of the apatite and apatite/
whitlockite mineral deposition in the aorta was further
investigated by performing 10 mm step size line scans through
the vascular wall. At each point, the calcium fluorescence
(Figure 2, upper panels) and diffraction pattern (Figure 2,
lower panels) were recorded simultaneously. In all samples
positive for poorly crystalline apatite or a combination of
apatite and whitlockite, amorphous precipitate was found at
the edges of the calcified region (upper panels of Figure 2a
and b, shaded zone) as indicated by a positive calcium signal
in the absence of a diffraction pattern (Figure 1d). Moreover,
in samples where the mineral was identified as a mixture of
whitlockite and apatite, the fluorescence/diffraction line scan
analysis showed areas positive (Figure 2b, left diffraction
pattern) and negative (Figure 2b, right diffraction pattern)
for the presence of whitlockite indicating a heterogenic
distribution of this mineral phase in the vessel wall of
calcitriol-treated animals.
Table 1 | Distribution of the different mineral phases in the
investigated aortic regions
Amorphous
precipitate Apatite
Apatite/
whitlockite
Adenine model 1 7 0
Calcitriol-treated remnant
kidney model
11 9 10
w2 analysis revealed significant proportional differences (P=0.012) in the occurrence
of the mineral phases between the two rat models.
a
b
c
d
P
Ca
Interplanar d-spacing 
(nm)
Interplanar d-spacing 
(nm)
Interplanar d-spacing 
(nm)
Amorphous precipitate Apatite Apatite / Whilockite
1.5 2 3 4.53.52.5 54 1.5 2 3 4.53.52.5 54 1.5 2 3 4.53.52.5 54
Figure 1 | Mineral identification in the calcified aorta of uremic rats. (a) Based on a video microscopic image of the aortic wall a region
of interest was defined which was further investigated by means of X-ray fluorescence mapping for the presence of (b) phosphorus and
(c) calcium (Bar¼ 50mm). By performing several line scans through the region of interest X-ray diffraction patterns were recorded and
averaged over the line scan. (d) After the circular integration of the recorded diffraction patterns (see Materials and Methods) the mineral phase
of the investigated aortic region could be identified either as (i) amorphous precipitate, (ii) apatite, or (iii) a mixture of apatite and whitlockite.
In some aortic regions the calcium phosphate was present as an amorphous precipitate whereas in others the mineral could be identified
as calcium apatite (black arrow heads). Only samples originating from the vitamin D-treated renal failure animals next to apatite
(black arrow heads) also an additional mineral phase was found, identified as whitlockite (open arrow heads).
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As the formation of whitlockite has been associated with
the presence of magnesium,17,18 serum and mineralized
aortas of both models were analyzed for their calcium and
magnesium content. No difference in serum magnesium
concentration was found (0.03770.019 vs 0.03270.019mg/ml
magnesium in adenine treated vs calcitriol treated 5/6
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Figure 2 | Calcium X-ray fluorescence and X-ray diffraction patterns of the deposited mineral in the aorta of uremic rats. Representation
of the ultrastructural spatial heterogeneity of the identified mineral phases: (a) apatite and (b) apatite and whitlockite. These mineral phases
were further investigated by performing line scans with a 10 mm step size through the vessel wall. During this line scan patterns both X-ray
fluorescence for calcium (upper panel) and diffraction (lower panel) were recorded for each 10 mm step. The integrated diffraction pattern for
each point of the line scan is presented in the lower panel as percentage of maximum peak intensity in a 2D-height-field. The gray shaded
regions in the calcium signal in the upper panel for (a) apatite and (b) apatite and whitlockite represent the scan points where no mineral
phase but amorphous calcium phosphate phase was found. The white dotted line through the diffraction height-field marks the position of the
detailed diffraction patterns shown left (whitlockite) and right (apatite). The white arrow heads indicate the diffraction peak positions typical for
whitlockite whereas the black arrow heads indicate the apatite peaks. These data also show that the whitlockite mineral phase is not
homogeneously distributed through the aortic calcification.
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nephrectomized rats, respectively). In contrast, the calcified
areas of the aorta obtained from subtotally nephrectomized
animals loaded with calcitriol showed a significantly
(Po0.001) higher magnesium/calcium ratio compared to
rats with adenine-induced renal failure receiving a high-
phosphate diet (median: 0.63, range: 0.12–1.28 (mean7s.d.:
0.4870.23) vs median: 0.22, range: 0.09–0.69 (mean7s.d.:
0.3270.18); Figure 3).
DISCUSSION
Recent in vitro studies have shown that vascular calcification
is a tightly regulated process in which the vascular smooth
muscle cell undergoes a trans-differentiation towards an
osteogenic phenotype.12 In vitro data further suggest that the
mineral compound present in the vascular wall is micro-
crystalline apatite,9,13,19 as it naturally occurs in bone. Indeed,
the presence of hydroxyapatite in the aorta of uremic rats was
suggested as early as 1979 by the application of X-ray
fluorescence micro analysis.20 This technique, however, only
provides information concerning the elemental composition,
and does not allow the identification of the mineral phase. In
an autopsy study of patients with end-stage renal disease,
hydroxyapatite and calcium phosphate were found in
calcified atherosclerotic plaques by the application of X-ray
diffraction.21 Although these observations20,22 have provided
valuable information on the nature of severe atherosclerotic
lesions, much less is known of the physicochemical properties
of mineral deposits in the vascular media in uremia. Such
information might further contribute to the unraveling of the
mechanisms leading to the formation/possible reversal of
vascular calcification in renal disease.
In the present study, two frequently used models of
uremia-related vascular calcification were compared at the
level of deposited mineral. Interestingly, between the
investigated models a significantly difference in distribution
of mineral phases (both amorphous calcium phosphate and
whitlockite) was found.
Calcium phosphate precipitating from a supersaturated
solution in vitro is initially an amorphous compound which
is converted into the thermodynamically more stable
microcrystalline apatite form.17 This process occurs also in
biological mineralization such as in bone formation.23,24
Hence, in the frame of the current study it is not surprising
that both amorphous calcium phosphate and poorly crystal-
line apatite were present in the calcified aorta of uremic rats
exposed to either calcitriol and/or a high-phosphate diet. The
application of synchrotron X-ray-m-diffraction with an X-ray
probe size of 2 10 mm enabled us to study the spatial
heterogeneity of the mineral phase in the vascular media at
the ultrastructural micrometer-scale level. This evaluation
showed the presence of amorphous calcium phosphate at the
edges of the mineral phases. This observation fits well with
previous findings in that the amorphous calcium phosphate
precipitate is an early deposit which matures over time under
the formation of calcium apatite.17 Moreover, as amorphous
calcium phosphate is a labile precipitate its presence suggests
that the mineral deposition in vascular calcification may be
reversible at these sites.
Surprisingly, in 1/3 of the aortic regions of animals
exposed to calcitriol, the mineral phase consisted not only of
apatite but contained also whitlockite, which is a calcium-
magnesium orthophosphate, that is, (Ca,Mg)3(PO4)2.
18,17
Already at low concentrations, magnesium ions have a
marked effect on nucleation and growth of calcium
phosphates. These ions delay the conversion of amorphous
calcium precipitates to the more stable apatite phase and
promote the formation of whitlockite.17,18,25 As (i) X-ray
diffraction only offers information on mineral lattice
characteristics, but not of the mineral composition, and (ii)
the applied X-ray-m-fluorescence technique was not suitable
to detect chemical elements with low atomic number, such as
magnesium, flame atomic absorption spectroscopy was used
to determine the bulk magnesium content in calcified aortas
of both models of vascular calcification. The presence of a
significantly higher magnesium/calcium ratio in the aortas of
calcitriol-treated animals vs the adenine-treated rats strongly
supports the presence of whitlockite. These new findings are
in line with previous observations showing that calcitriol
supplementation not only stimulates calcium and phos-
phorus uptake but also favors the gastrointestinal absorption
of magnesium.26,27 As under normal physiological conditions
the kidney plays a central role in the metabolism of
magnesium it is not surprising that magnesium accumula-
tion occurs in the presence of renal failure.28
The observed difference in mineral composition between the
two investigated models of uremia-related vascular calcification
cannot be ascribed to the methodology applied inducing
chronic renal failure as the degree of renal impairment and
other biochemical parameters (Ca P product and parathy-
roid hormone) were comparable. The only significant
difference between both models was the duration of uremia,
P<0.001
1.4
1.2
0.8
0.6
0.4
0.2
1
0
M
g/
Ca
 ra
tio
 o
f c
al
cif
ie
d 
ao
rta
Calcitriol-treated 
remnant
kidney model
Adenine
 model
Figure 3 | Magnesium/calcium ratios of the calcified aortas in
both models. Statistical evaluation of the data with a Mann–Whitney
test showed a significantly (Po0.05) higher magnesium/calcium ratio
in the aortas of vitamin D-treated 5/6 nephrectomized rats vs
adenine-treated animals receiving a high-phosphate diet.
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with a three weeks longer period in renal insufficiency in the
adenine-treated rats. This has the consequence that the
deposited precipitate in the adenine-treated rats had a longer
maturation time. This, together with the possible effects of
magnesium delaying the formation of stable apatite in the
calcitriol-treated animals can explain the difference in distribu-
tion of the amorphous phase between both models.
Recently, a link between the status of bone metabolism
and vascular calcification has been made.29 In this context it
has to be noted that it has been reported that adenine
treatment not only induces chronic renal failure but also
affects steroidogenesis and reduces bone metabolism result-
ing in a reduced bone mineral density.30 Although the male
gender and a reduced bone mineral density have been
considered as risk factors for the development of vascular
calcification, such an effect can be excluded as histomorpho-
metric analysis of bone samples of the adenine-treated
animals did not show a reduced bone area or signs of a
reduced bone mineral density. Instead a histological picture
of secondary hyperparathyroidism was found (Persy et al. SA-
PoO950, ASN, Renal Week 2004). Because of the high-
phosphate diet in combination with the severe renal failure,
the vitamin D-treated animals also showed the histological
features of secondary hyperparathyroidism.
The physiopathological role and clinical importance of
whitlockite is much less studied compared to apatite and its
relevance may have been largely underestimated as the
classical Von Kossa staining for calcified tissues does not
allow to differentiate between whitlockite and apatite.
Techniques such as X-ray or electron diffraction and infrared
spectrometry that allow discrimination between mineral
phases are not routinely applied on biological/pathological
samples. To the best of our knowledge only one publication is
available in literature that mentions the presence of
whitlockite in the vascular media of autopsy samples of
subjects of the general population.31 In contrast with our
findings, however, in the latter paper no microanalysis was
performed, nor was the heterogeneity of the mineral phase
investigated. Moreover, the occurrence of whitlockite in
arterial calcifications in uremic patients and its association
with calcitriol treatment has not been described previously.
Our results indicate that the process of uremia-related
vascular calcification is not solely owing to the deposition
of calcium-apatite and that a role for magnesium in the
pathogenesis of uremia-related calcification should be
considered – especially during calcitriol treatment.
MATERIALS AND METHODS
This study was performed as an extension of two previous studies on
either the effect of adenine treatment and a high-phosphate diet16 or
a 5/6 nephrectomy and calcitriol-treatment15 on the induction of
vascular calcification.
Animal models
Medical vascular calcifications were induced in two models of
chronic renal failure.
Adenine model of chronic renal failure. Chronic renal failure
was induced by feeding male Wistar rats a diet containing 0.75%.
adenine and 0.92% phosphorus for 4 weeks, which has been shown
to induce a stable, moderate to severe renal function impairment.32
Following adenine treatment the animals (N¼ 13) were fed a diet
containing 1.06% calcium and 1.03% phosphorus during 6 weeks
until killing.16
Remnant kidney model of chronic renal failure. Male
Sprague–Dawley rats underwent a 5/6 nephrectomy to induce
chronic renal failure. Two days after surgery (day 0), the animals
received 0.25 mg/kg. of 1,25(OH)2D3 (Rocaltrol
TM, Roche, Man-
nheim, Germany) postoperatively daily for 6 weeks. Animals
(N¼ 12) received a standard commercial diet containing 1.2%
phosphorus, 0.9% calcium (AltrominTM, Altromin Co., Lage,
Germany).15
Sample preparation
Through a combined midline laparotomy and thoracotomy the
vascular tree was exposed and the large vessels were removed ‘en
bloc’. The aorta was divided in different pieces; one piece was used
for general histology after paraffin embedding, another was
embedded with methyl methacrylate for mineral identification,
whereas a third part was used for bulk analysis.
Methyl methacrylate embedding of the aorta samples was
performed using a standard procedure as reported elsewhere.33 A
10-mm thick methyl methacrylate-embedded aorta section was used
for evaluation of the mineral deposition in the vessel wall by
Von Kossa staining and counterstaining with hematoxylin and
eosin. Another 10 mm section (adjacent to the Von Kossa-stained
section) was dried unstained between two glass cover slides at 601C,
and used for synchrotron X-ray-m-fluorescence and X-ray-m-dif-
fraction analysis.
Analysis of serum and bulk tissue calcium and magnesium
content
Unfixed tissue samples were weighed with a precision balance and
subsequently digested in 65% nitric acid at 651C overnight. Serum
and tissue calcium and magnesium content was measured by flame
atomic absorption spectrometry (Model 3110, Perkin-Elmer, Nor-
walk, CT, USA) after appropriate further dilution of the samples in
0.1% lanthanum nitrate to avoid chemical interferences.
Mineral identification
Unstained 10-mm thick methyl methacrylate-embedded aorta
sections adjacent to those stained positive for Von Kossa were
investigated by X-ray-m-analysis. Several regions of interest were
defined on each sample which were investigated by synchrotron
X-ray-m-fluorescence and X-ray-m-diffraction on beam line ID18F
of the European Synchrotron Radiation Facility (Grenoble,
France)34 applying a same beamline set-up as published before.35
The optimum step-size for either raster or line scans is determined
by the size of the focused beam (2 10 mm) and was set to 10mm in
both directions (horizontally and vertically). Calcium and phos-
phorus mapping were obtained by integrating the fluorescence
intensities defined by the appropriate energy windows for the
respective element (calcium: 3.47–4.24 keV and phosphorus:
1.81–2.13 keV) during a recording time of 1 s.
Integration of the obtained circular X-ray-m-diffraction patterns
to d-spacing format (d¼ interplanar or interatomic distance) was
carried out using the X-ray diffraction software package FIT2D
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developed by Hammersley et al.36 Comparison with the reference
diffraction spectra for synthetic hydroxyapatite (Ca10(PO4)6(OH)2:
PDF #86-0740) and whitlockite ((Ca,Mg)3(PO4)2: PDF #70-2064)
from the powder diffraction database PCPDFWIN version 2.1
(International Centre of Diffraction Data, USA) was performed after
background correction of the integrated X-ray diffraction spectra.
Statistics
Results of the bulk analysis of the magnesium/calcium ratio in the
rat aorta were analyzed for significant differences using the non-
parametric Mann–Whitney test. Comparison of the prevalence of
the various mineral phases in the two models was carried out by w2
analysis. P-values o0.05 (two tailed) were considered as significant.
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